false 0001701541 0001701541 2024-01-17 2024-01-17 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

The UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 17, 2024

 

 

BLACK DIAMOND THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

 

     
Delaware 001-39200 81-4254660
(State or other jurisdiction (Commission (I.R.S. Employer
of incorporation) File Number) Identification No.)

 

One Main Street, 14th Floor    
Cambridge, Massachusetts   02141
(Address of Principal Executive Offices)   (Zip Code)

 

(617) 252-0848

(Registrant’s telephone number, including area code)

 

Not Applicable
(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation to the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class Trading Symbol(s) Name of each exchange on which
registered
Common Stock, $0.0001 par value per share BDTX The Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

On January 17, 2024, Rajeev Shah notified Black Diamond Therapeutics, Inc. (the “Company”) of his intent to resign from the Company’s Board of Directors (the “Board”), including his position as a member of the Audit Committee of the Board, effective immediately. Mr. Shah served as a member of the Board since December 2018. Mr. Shah’s decision to resign from the Board was not the result of any disagreement with the Company on any matter relating to the operations, policies or practices of the Company.

 

Item 9.01.Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
104   Cover Page Interactive Data File (embedded within the Inline XBRL document).

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  BLACK DIAMOND THERAPEUTICS, INC.
     
     
Date: January 18, 2024 By: /s/ Brent Hatzis-Schoch
  Name: Brent Hatzis-Schoch
  Title: Chief Operating Officer and General Counsel

 

 

v3.23.4
Cover
Jan. 17, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 17, 2024
Entity File Number 001-39200
Entity Registrant Name BLACK DIAMOND THERAPEUTICS, INC.
Entity Central Index Key 0001701541
Entity Tax Identification Number 81-4254660
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One One Main Street, 14th Floor
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02141
City Area Code 617
Local Phone Number 252-0848
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.0001 par value per share
Trading Symbol BDTX
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
Black Diamond Therapeutics (NASDAQ:BDTX)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more Black Diamond Therapeutics Charts.
Black Diamond Therapeutics (NASDAQ:BDTX)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more Black Diamond Therapeutics Charts.